Monday 30 June 2025

Pharma & Biotech Start-up & Scale-up News

Featured

Altimmune
A clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease.
Pharmaceutical
Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk
28 March 2025
Pharmaceutical
Lexicon pivots back to pipeline after FDA rejection
25 November 2024

Latest Ones To Watch News

Biotechnology
Hummingbird licenses antibody in deal worth up to $290 million
26 June 2025
Biotechnology
Novartis inks deal with ProFound on cardio diseases
26 June 2025
Biotechnology
Vor Bio licenses telitacicept from RemeGen
26 June 2025
More ones to watch news >
Reset all filters
Refine Search
Nuvalent
Nuvalent
UroGen Pharma
UroGen Pharma
Tubulis
Neurocrine Biosciences
Axsome Therapeutics
Cidara Therapeutics
Halda Therapeutics
Opthea
OncoZenge
Soleno Therapeutics
GAIA
Alligator Bioscience
Pliant Therapeutics
Nuvation Bio
Enanta Pharmaceuticals
Basilea
Exsilio Therapeutics
Aphaia Pharma
Avextra
Aurion Biotech


Today's issue

The week in pharma: action, reaction and insight – week to June 27
Pharmaceutical
The week in pharma: action, reaction and insight – week to June 27
29 June 2025
Biotechnology
BioCryst to sell European Orladeyo business
28 June 2025
article
FDA approves Gamifant for HLH/MAS in Still’s disease
28 June 2025
Biosimilars
Formycon increases bond volume following oversubscription
28 June 2025
Pharmaceutical
Arbutus regains global rights to imdusiran following Qilu exit
27 June 2025
Biotechnology
Calico signs $571 million licensing deal with Mabwell for IL-11 drug
27 June 2025
Pharmaceutical
Bayer extends long-standing Tsinghua University partnership
27 June 2025

Company Spotlight

A clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease.




Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze